Fang Liu, MD
Enriched profileInternist, Marietta GA (third-party listing; specialty conflicts with the hematology board note on the same page) · Northwest Georgia Oncology Centers
Fang Liu is Internist, Marietta GA (third-party listing; specialty conflicts with the hematology board note on the same page) at Northwest Georgia Oncology Centers. ClinicalTrials.gov lists 26 registered studies with this person as an investigator.
Data verified 27 Oct 2026
Overview
Updated 31 Oct 2026
Fang Liu, M.D., is Internist, Marietta GA (third-party listing at Northwest Georgia Oncology Centers. It also documents an investigator role on 26 registered clinical trials, industry payments reported by 17 companies.
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 26 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 31 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Oct 2026
Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:
- Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
Sponsor: Children's Hospital of Fudan University
- Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
Sponsor: The Third Affiliated Hospital of Harbin Medical University
- Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
Sponsor: Children's Hospital of Fudan University
Industry payments
Updated 31 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20254 payments
- BeOne Medicines USA, Inc.Program year20253 payments
- Daiichi Sankyo Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.6%Aromatase Inhibitor25.5%Anastrozole80%Letrozole17%Exemestane3%Part D<11 patientsKinase inhibitor12.7%Calquence19%Ibrance15%Verzenio13%Jakafi12%Cabometyx10%Imbruvica8%Imatinib Mesylate7%Brukinsa6%Kisqali5%Tasigna5%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
16.2%Corticosteroid7.3%Prednisone100%Part D≥42 patientsSerotonin-3 Receptor Antagonist2.6%Ondansetron Hcl76%Ondansetron Odt24%Part D<11 patients+ 5 more classes in this area
Blood & clotting
10%Factor Xa inhibitor7.6%Eliquis60%Xarelto40%Part D≥24 patientsVitamin K antagonist1.7%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Background & recognition
Updated 31 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connect.medicalnewstoday.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connect.medicalnewstoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center